STANDARD BIOTOOLS INC.
LABNasdaqHealthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M | $138.1M |
| Operating income | −$110.2M | −$127.5M | −$76.6M | −$116.2M | −$67.5M | −$51.0M |
| Net income | −$74.9M | −$138.9M | −$74.7M | −$190.1M | −$59.2M | −$53.0M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M | $324.8M |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M | $180.6M | $185.7M |
| Equity | $424.3M | $471.7M | −$148.1M | −$81.5M | $94.6M | $139.1M |
| EPS (diluted) | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 | $-0.74 |
| Shares out. | 379.0M | 290.1M | 79.1M | 77.2M | 74.5M | 70.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −129.2%
- Net margin
- −87.8%
- Return on equity
- −17.7%
- Return on assets
- −13.2%
- Return on capital (ROCE)
- −24.0%
- Liabilities / assets
- 25.3%
- Debt / equity
- 0.34×
- Book value / share
- $1.12
- Revenue growth (YoY)
- −6.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.44distress
- Accruals / assets
- −0.1%clean
- Beneish M-Score
- -2.80normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 12, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Mak Capital Fund LpPassive (13G)May 15, 2026
- Viking Global Investors LpPassive (13G)May 15, 2026
- Casdin Capital, LlcActivist (13D)Nov 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 12.9M | 7.0 | +9.3% |
| Apr 30, 2026 | 11.8M | 4.3 | +39.4% |
| Apr 15, 2026 | 8.5M | 2.4 | -17.8% |
| Mar 31, 2026 | 10.3M | 5.6 | +24.6% |
| Mar 13, 2026 | 8.3M | 2.5 | -18.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 28, 2026
- Results of operations · Regulation FD disclosureMay 5, 2026
- Delisting / listing-standard noticeApr 24, 2026
- Results of operations · Regulation FD disclosureFeb 24, 2026
- Completed an acquisition or disposition · Results of operations · Regulation FD disclosureJan 30, 2026
- Results of operationsJan 8, 2026
- Results of operations · Regulation FD disclosureNov 4, 2025
- Costs from exit or disposalSep 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.